Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
Ohr Pharmaceutical Provides Update to Shareholders on 2012 Accomplishments and Milestones for 2013

NEW YORK, Dec. 27, 2012 /PRNewswire/ -- Ohr Pharmaceutical Inc., a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets, announced today that it has published a letter to shareholders, available on the Company's website, from its Chief Executive officer, Dr. Irach B. Taraporewala, Ph.D. The letter states:

Dear Shareholder,

I would like to take this opportunity to share the progress we have made in 2012 and lay out the milestones we aim to achieve in 2013:

2012 Accomplishments

  • Initiated Phase 2 clinical trial with Squalamine Eye Drops for the treatment of wet-AMD: The Phase 2 trial (OHR-002) will evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration ("wet-AMD"). The randomized, double blind, placebo controlled study is enrolling patients at large ophthalmology treatment centers across the United States. Interim results are expected in the fourth quarter of 2013. We believe an eye drop to treat wet-AMD and ophthalmic neovascular disorders would be transformational for the large patient populations currently taking chronic treatments of Lucentis® or Eylea®, both of which are injected directly into the eye.
  • Strengthened balance sheet: The Company completed a $2.9 million dollar financing with a group of existing shareholders at favorable terms. We are now well financed to continue the clinical development of our pipeline compounds.
  • Squalamine eye drop data: We completed several preclinical studies to support our Phase 2 clinical trial for the treatment of wet-AMD. The studies demonstrated:
    • Therapeutically relevant concentrations in the tissues of the back of the eye
    • The ability to maintain those concentrations consistently
    • Ocular and systemic safety when administered over a long period of time

    Data was presented at the Association for Research in Vision and Ophthalmology (ARVO) conference in May. Dr. Michael Elman, a member of our scientific advisory board, also made an oral presentation, at the Macula Society 2012 meeting, which outlined the clinical relevance of Squalamine eye drops and its potential utility in neovascular ophthalmic disorders.
  • FDA Fast Track designation: In May, the U.S. FDA granted our Squalamine eye drop program with Fast Track designation for the treatment of wet-AMD. Fast track designation is awarded to programs that meet specific criteria which includes programs that demonstrate the potential to treat an unmet medical need. Fast track status will provide us with many advantages to potentially accelerate development of the Squalamine eye drop program, such as more frequent meetings with the FDA and the potential for Priority Review.
  • Formation of World Class Scientific Advisory Board: We assembled an ophthalmic scientific advisory board consisting of seven top thought leaders in the treatment of retinal disorders and other ophthalmology indications. These thought leaders have been actively involved in the clinical development of therapeutics approved by the FDA for wet-AMD (Lucentis ® and Eylea®), and are at the leading edge of research into novel therapeutics for retinal disorders.
  • Strengthening of patent portfolio: In 2012, we were granted several key patents on our Squalamine and OHR/AVR118 programs including composition of matter and method of use claims. Additional applications have been filed and we plan to continue expanding our intellectual property portfolio.
  • Increased market awareness and visibility: During 2012, we amplified our efforts to increase market awareness and visibility of our exciting story through road show meetings with institutional investors, presentations at investor conferences, online and print articles, and social media. Of particular note, are the recent research coverage initiations from two Wall Street firms, Burrill & Company and Brean Capital.  This increased investor awareness coupled with continued business execution has resulted in a tremendous increase in shareholder value in 2012.

Anticipated 2013 Milestones

  • Completion of OHR/AVR118 Trial and Data Presentation: Enrollment of the OHR/AVR118 trial is complete and we will present top line data from the phase II trial in the first quarter of 2013. The interim analysis from the current trial demonstrated positive effects and mitigation of multiple symptoms of cachexia, including increase in appetite. Cachexia is a severe wasting disorder often seen in late stage cancer patients which is highly debilitating and diminishes their quality of life. There is currently no FDA approved therapy for cancer cachexia.
  • Interim Data from Squalamine Eye Drops Phase 2 Trial: The OHR-002 study to evaluate the efficacy and safety of Squalamine eye drop for the treatment of wet-AMD patients continues to enroll patients. The protocol includes a predetermined interim analysis when 50% of the patients have completed the nine month treatment period, and we expect to have those results in the fourth quarter of 2013.
  • Uplisting to a national exchange: Based on our strengthened financial position, we are planning on moving our listing to a larger national exchange and expect to do so by the end of the second quarter.
  • Progress of additional indications and pipeline molecules: In 2013, we expect to present additional data from a completed phase IIa study of Squalamine in resistant ovarian cancer, an Orphan Drug indication, and continue to progress with Trodusquemine and related compounds currently undergoing preclinical testing in a yet undisclosed indication.

Our programs have the ability to meet large unmet medical needs in large and growing, well established markets. Wet-AMD in particular, is an area that has received a lot of attention lately with the successful launch of Regeneron's (REGN) Eylea® and the continued commercial success of Roche/Genentech's (RHHBY) Lucentis®, which are likely to have worldwide revenues for 2012 in excess of $4 billion.

I thank you for your ongoing support and I look forward to updating you in the future as we continue to progress with our exciting development programs.

Best regards,
Irach B. Taraporewala
Chief Executive Officer

About Ohr Pharmaceutical Inc.
Ohr Pharmaceutical Inc. (OHRP) is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The company is focused on two lead compounds currently being investigated in clinical phase II trials: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia. Additional information on the company can be found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

Contact:
Investor Relations:
Tel: (877) 215-4813
Email: ir@ohrpharmaceutical.com

SOURCE Ohr Pharmaceutical Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SOA World Latest Stories
With the capability to reduce both CapEx and OpEx, it’s easy to see why the SDN-NFV trend has taken hold in the hosting and mobile industry. Early use cases include network virtualization from cloud service providers and enterprise data centers, bandwidth calendaring and network tappin...
In this challenging environment, a combination of automated integration testing and test virtualization can enable test teams to improve software quality and keep up with the rate of change. This white paper helps address these needs by describing the benefits that can be gained throug...
The Domain Name Service (DNS) is one of the most important components in networking infrastructure, enabling users and services to access applications by translating URLs (names) into IP addresses (numbers). Because every icon and URL and all embedded content on a website requires a DN...
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is ob...
Cloudian on Tuesday announced immediate availability of Cloudian HyperStore appliances and Cloudian HyperStore 5.0 software. Flash-optimized, rack-ready HyperStore appliances make it easy to economically deploy full-featured, highly scalable S3-compliant storage with three enterprise-f...
WaveMaker on Tuesday announced WaveMaker Enterprise, licensed software that enables organizations to run their own end-to-end application platform as a service (aPaaS) for building and running custom apps. WaveMaker Enterprise is a commercially available rapid API app development and d...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE